Provectus Biopharmaceuticals, Inc. announced changes to the company’s Board of Directors, effective April 27, 2018. Edward V. (“Ed”) Pershing, CPA and John W. “Jack” Lacey, III, MD were appointed new Board members; Mr. Pershing was originally appointed an observer of the Board and all Board committees, and Mr. Pershing and Dr. Lacey were appointed chair and a member, respectively, of Provectus’ strategic advisory board on April 20, 2017. Mr. Pershing was elected new Board chair; former Board chair Dominic Rodrigues was elected Board vice chair. Eric Wachter, PhD stepped down from the Board; he remains the Company’s Chief Technology Officer.